Dual Task Walking, Electromyography, Parkinson Disease (PD)
Conditions
Keywords
Parkinson Disease, Gait Disorders, Neurologic, Dual-Task Tests, Muscle Contraction, Wearable Electronic Devices
Brief summary
In this observational study embedded within a randomized controlled trial, the investigators aim to characterize the activation patterns of the tibialis anterior and medial gastrocnemius muscles in the more rigid leg of patients with Parkinson's disease when performing walking tasks under dual cognitive-task conditions, which are known to increase the risk of falls in this population. To this end, a control group without neurological disorders and with comparable sociodemographic characteristics will also be assessed. The study seeks to determine whether significant changes occur in forward and backward gait as a function of the dual-task condition.
Interventions
None listed
Sponsors
University of Cadiz
Hospital Universitario Virgen Macarena
Facultad de Enfermería, Fisioterapia y Podología (FEFP)
Asociación de Enfermos de Parkinson de Sevilla
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Ability to walk independently for at least 5 meters, both forward and backward, without the need for assistive devices or assistance from another person. * Diagnosis of idiopathic Parkinson's disease made by a neurologist at Hospital Virgen Macarena. * Hoehn and Yahr stage I-III. * Being in the "ON" phase of antiparkinsonian medication during the assessment (approximately one hour after intake, when the pharmacokinetic curve of levodopa reaches its peak).
Exclusion criteria
* Presence of symptomatic musculoskeletal disorders affecting the lower limbs (LL) (relevant orthopedic surgery or leg length discrepancy \> 1 cm), or other neurological conditions (stroke, neuropathies, etc.) that independently affect gait. * Balance disorders due to other causes (vestibulopathy, severe orthostatic hypotension, etc.). * Decompensated systemic diseases (cardiac disease, COPD, uncontrolled diabetes mellitus, etc.). * Uncorrected visual impairments that may affect gait performance. * Previous treatment with deep brain stimulation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| %MIVC | Baseline (Day 1) | It was calculated by expressing the Root Mean Square (RMS) value for each condition as a percentage of the Maximal Voluntary Contraction (MVC) obtained during the isometric test. This approach ensures accurate quantification of neuromuscular effort, which is essential to minimize bias arising from anatomical and physiological differences between subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CVM | Baseline (Day 1) | The Maximal Voluntary Contraction (MVC) was established as the reference value for neuromuscular activation capacity for each muscle (TA and GM). This variable was obtained as the mean of three repetitions of maximal isometric activation lasting 6 seconds, allowing standardization of muscle responses to the dynamic efforts performed during gait. |
| Ratio (GM/TA) | Baseline (Day 1) | It is calculated as the ratio of activation between the agonist and antagonist muscles during the gait cycle. This index is used to assess muscle co-activation strategies and the mechanical efficiency of gait. |
Countries
Spain
Outcome results
None listed